
⸺ Synova Research
Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.
Website checkout coming soon — for now, orders are placed directly via our Telegram. Fast replies & secure payment links.
Independently tested
COA on request
Next-day UK dispatch
Order before 2pm
Research use only
Not for human consumption
⸺ Important
⸺ Overview
Semaglutide is a long-acting GLP-1 receptor agonist used extensively in preclinical and clinical research. It mimics the body's natural incretin response and is commonly evaluated in models related to metabolic function and weight regulation.
⸺ Mechanism of Action
Semaglutide binds the GLP-1 receptor, prompting glucose-dependent insulin secretion, suppressing glucagon release and slowing gastric emptying. The result, in animal models, is improved glycaemic control and reduced food intake.
⸺ Research
Rodent and primate studies have repeatedly demonstrated improved fasting and post-prandial glucose levels with Semaglutide administration.
Animal models consistently show reduced food intake and body-weight changes, making Semaglutide a benchmark for incretin-based metabolic research.
Preclinical work has explored changes in lipid panels and inflammatory markers under chronic Semaglutide exposure.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details

Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.

Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.

Long-acting amylin analogue researched for appetite regulation and weight management, often paired with GLP-1 agonists in metabolic studies.